[
  {
    "ts": null,
    "headline": "TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?",
    "summary": "Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.",
    "url": "https://finnhub.io/api/news?id=18acc91df86a9786cd20206392a2ac9ef4a8f3508da58bab83703ac8d303292f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756999800,
      "headline": "TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?",
      "id": 136642299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.",
      "url": "https://finnhub.io/api/news?id=18acc91df86a9786cd20206392a2ac9ef4a8f3508da58bab83703ac8d303292f"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Industry Veteran Scott Rairigh Joins Psilera to Lead Corporate Development",
    "summary": "Psilera, Inc. (\"Psilera\"), a biotechnology company developing groundbreaking therapies for complex neurological disorders, has appointed Scott W. Rairigh as Executive Vice President of Corporate Development. In this capacity, Rairigh will oversee business development, investor relations, and commercialization strategies as the company moves its medicines closer to the clinic.",
    "url": "https://finnhub.io/api/news?id=3f88cc8814d2a91de573e982acabd00a3b4ce3cbfd6abcba6387ca4f2fe597fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756991700,
      "headline": "Healthcare Industry Veteran Scott Rairigh Joins Psilera to Lead Corporate Development",
      "id": 136642300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Psilera, Inc. (\"Psilera\"), a biotechnology company developing groundbreaking therapies for complex neurological disorders, has appointed Scott W. Rairigh as Executive Vice President of Corporate Development. In this capacity, Rairigh will oversee business development, investor relations, and commercialization strategies as the company moves its medicines closer to the clinic.",
      "url": "https://finnhub.io/api/news?id=3f88cc8814d2a91de573e982acabd00a3b4ce3cbfd6abcba6387ca4f2fe597fa"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks to Buy With Less Than $50",
    "summary": "These stocks are cheap in more ways than one.",
    "url": "https://finnhub.io/api/news?id=97c3c62d1edeefc351005a04053c765bcb576513dbc32a8ff9c6cb39c16cef37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756990380,
      "headline": "2 Top Dividend Stocks to Buy With Less Than $50",
      "id": 136642158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "These stocks are cheap in more ways than one.",
      "url": "https://finnhub.io/api/news?id=97c3c62d1edeefc351005a04053c765bcb576513dbc32a8ff9c6cb39c16cef37"
    }
  },
  {
    "ts": null,
    "headline": "3 Things You Need to Know if You Buy Pfizer Today",
    "summary": "Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?",
    "url": "https://finnhub.io/api/news?id=2213766ccce6b9991bf12bc13becc1057b10ad016cb0cd3e8c42d37379899bca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756986300,
      "headline": "3 Things You Need to Know if You Buy Pfizer Today",
      "id": 136641988,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?",
      "url": "https://finnhub.io/api/news?id=2213766ccce6b9991bf12bc13becc1057b10ad016cb0cd3e8c42d37379899bca"
    }
  },
  {
    "ts": null,
    "headline": "How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?",
    "summary": "Bristol-Myers Squibb has notably underperformed the broader pharma space over the past year, and analysts have turned cautious on the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=4f73a09ce7b722a2b2a155a1c4d7b329ed38c8886e8e4dd5db5582b18f7129da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756973608,
      "headline": "How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?",
      "id": 136642303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb has notably underperformed the broader pharma space over the past year, and analysts have turned cautious on the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=4f73a09ce7b722a2b2a155a1c4d7b329ed38c8886e8e4dd5db5582b18f7129da"
    }
  },
  {
    "ts": null,
    "headline": "2 Large-Cap Stocks Worth Your Attention and 1 We Brush Off",
    "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
    "url": "https://finnhub.io/api/news?id=92c8b1747ed8c674250bc342e0aff17d1bd2aff716bc7676d97ab5decc05e951",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756964562,
      "headline": "2 Large-Cap Stocks Worth Your Attention and 1 We Brush Off",
      "id": 136642304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
      "url": "https://finnhub.io/api/news?id=92c8b1747ed8c674250bc342e0aff17d1bd2aff716bc7676d97ab5decc05e951"
    }
  }
]